Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company specializing in the development and implementation of clinical treatment solutions, including psychedelic medicines and digital therapeutics. The company offers ketamine-assisted therapy, psychedelic medicine treatment programs, and digital therapeutic products through a network of healthcare clinics across North America. Additionally, it operates a contract research organization subsidiary, KGK Sciences Inc., which provides high-quality clinical research trials, regulatory support, participant recruitment, and consulting services focused on nutraceuticals and emerging healthcare products. KGK Sciences also supports drug development through custom-designed clinical trials and claim substantiation strategies.
Founded in 2017 and headquartered in Vancouver, Canada, Wellbeing Digital Sciences focuses on mental health innovation by integrating AI-enhanced digital therapeutics alongside its psychedelic medicine offerings. Recent major changes include the divestiture of its KGK Sciences subsidiary through a share purchase agreement with Cardinal Group Companies LLC in 2023, marking a strategic shift to concentrate more on core mental health therapies and clinic operations. The company also pioneered a Health Canada-authorized Phase IIA clinical trial of a psilocybin drug for fragile X syndrome, collaborating with Nova Mentis Life Science Corp., with special regulatory approval for take-home dosing. Moreover, Wellbeing Digital Sciences has rebranded from its former name KetamineOne Capital Limited to reflect its broadened focus beyond ketamine therapies to the wider field of digital and psychedelic mental healthcare.
Wellbeing operates clinics providing IV ketamine therapy and services supporting clinical trial management and psychedelic research. It targets mental illness treatment markets in Canada and the U.S., leveraging a research-backed approach to innovative mental healthcare. The company's recent emphasis on expanding digital therapeutics, conducting advanced clinical trials, and engaging in strategic partnerships positions it as a next-generation wellness company focused on evidence-based psychedelic medicine and digital solutions for mental health disorders.
Najla Guthrie serves as the CEO, guiding the company's evolution and participation in prominent psychedelic and healthcare industry conferences. Wellbeing Digital Sciences seeks to become a leading healthcare model in North America for mental illness treatment by advancing innovative psychedelics and digital therapeutic interventions backed by rigorous clinical research.
This comprehensive approach encompassing clinical services, drug development trials, and digital therapeutics defines Wellbeing Digital Sciences Inc.'s operations and strategic focus as of late 2025.